06.05.2014
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler gets off to a positive start to the year
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key
word(s): Quarter Results
Eckert & Ziegler gets off to a positive start to the year
06.05.2014 / 07:45
---------------------------------------------------------------------
Press release
Eckert & Ziegler gets off to a positive start to the year
Berlin, May 6, 2014. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN
DE0005659700), a Berlin-based company specializing in isotope technology
for medical, scientific and industrial applications, increased sales by 16%
year on year in the first quarter of 2014 to EUR 30.7 million. All key
product groups reported sales increases, despite disadvantageous changes in
exchange rates; organic growth (especially with regard to industrial
components) was boosted by acquisitions (such as in the Cyclotron
business).
EBIT soared by 25% to EUR 3.0 million due to additional contribution
margins from the increase in sales as well as the absence of overall
negative special effects in the prior-year quarter. However, in the
Radiation Therapy segment, restructuring in the newly acquired companies in
the USA counteracted this effect and resulted in the first-ever quarterly
loss. As the losses reported by the Radiation Therapy segment are shared
with minority shareholders, they had less of an impact on the Group's net
profit for the quarter, which grew faster than EBIT - by 32% to EUR 1.6
million.
In the period from January to March 2014, liquidity fell EUR 4.3 million to
EUR 25.1 million. This was due to a 18% rise in net working capital
(increase in receivables and inventories) to EUR 36.4 million, greater
investments and higher loan repayments. The latter resulted in equity
increasing from 51% to 52%.
The Executive Board has confirmed the sales and earnings growth of at least
10% forecast for 2014 in the annual financial statements for 2013. In
concrete terms, sales are expected to grow to EUR 134 million and net
profit to EUR 10.5 million or EUR 2.00 per share.
The complete quarterly financial statements can be viewed under:
http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/engl
isch/euz114e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with
approximately 700 employees, is one the world's largest providers of
isotope technology for radiation therapy and nuclear medicine.
Contributing to saving lives.
For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str.
10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
End of Corporate News
---------------------------------------------------------------------
06.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
266457 06.05.2014
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ